Voedingssupplementen zijn geen vervanging van een gevarieerd evenwichtig voedingspatroon en een gezonde levensstijl
therefore, we may be underestimating the extent of therapy changes
The growth in the historic period can be attributed to rising prevalence of type 2 diabetes, increasing global obesity rates, limitations of traditional antidiabetic drugs, clinical success of glp-1 receptor agonists, growing physician confidence in injectable therapies
You dont need to be obese to start a GLP-1. In practice, though, you doat least according to the US Food and Drug Administration, which has only approved GLP-1 drugs for people with clinical obesity or Type 2 diabetes and for people who are overweight with weight-related comorbidities
But at the same time, they had other things going on